Eagle Pharmaceuticals, Inc. Deferred Tax Assets, Gross
Eagle Pharmaceuticals, Inc. had Deferred Tax Assets, Gross of $81.63 million as of 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsGross · last filed 2023-03-23
- 2022-12-31: Deferred Tax Assets, Gross $81.63M.
- 2021-12-31: Deferred Tax Assets, Gross $25.51M.
- 2020-12-31: Deferred Tax Assets, Gross $20.18M.
- 2019-12-31: Deferred Tax Assets, Gross $15.70M.
| Period end | Deferred Tax Assets, Gross |
|---|---|
| 2022-12-31 | $81.63M 10-K · filed 2023-03-23 |
| 2021-12-31 | $25.51M 10-K · filed 2023-03-23 |
| 2020-12-31 | $20.18M 10-K · filed 2022-03-08 |
| 2019-12-31 | $15.70M 10-K · filed 2021-03-05 |
| 2018-12-31 | $14.51M 10-K · filed 2020-03-02 |
| 2017-12-31 | $14.40M 10-K · filed 2019-02-28 |
| 2016-12-31 | $31.75M 10-K · filed 2018-02-26 |
| 2015-12-31 | $38.61M 10-K · filed 2017-03-15 |
| 2014-12-31 | $40.25M 10-K · filed 2016-02-29 |
| 2014-09-30 | $38.39M 10-K · filed 2016-02-29 |
| 2013-09-30 | $32.82M 10-K · filed 2016-02-29 |